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CONTINUING EDUCATION
Comparing the 2013 ACC/AHA & 2014 NLA Dyslipidemia Guidelines
and their Impact on Clinical Decision Making

by Alexander Forbes, Pharm.D. Candidate, Midwestern University College of Pharmacy-Glendale Class of 2015,
Kevin Grimes, Pharm.D.Candidate Midwestern University College of Pharmacy-Glendale Class of 2015, Jocelyn
York, Pharm.D. Candidate Midwestern University College of Pharmacy-Glendale Class of 2015, and Laura Tsu,
Pharm.D., BCPS, Assistant Professor, Pharmacy Practice, Midwestern University College of Pharmacy-Glendale
Goal:
This home-study CPE activity has been developed to
educate pharmacists on the similarities and differences
between the 2014 NLA Recommendations for Dyslipidemia Management and the 2013 ACC/AHA Guidelines for
Treatment of Blood Cholesterol.
At the conclusion of this CPE activity, successful participants should be able to:
Objectives for Pharmacists:
1. Identify the major differences in treatment recommendations for dyslipidemia between the 2013 ACC/AHA Guidelines
and the new 2014 NLA Recommendations for dyslipidemia.
2. List the classifications of lipoprotein lipid levels in adults.
3. Accurately identify targets for intervention in the treatment
of dyslipidemia.
4. Assess a patient’s ASCVD risk and the treatment goals based
on risk category.
5. Discuss lifestyle and drug therapies recommended to reduce
morbidity and mortality in patients with dyslipidemia.
6. Apply NLA guidelines to formulate and evaluate initial or
existing therapy to specific patient cases.
Objectives for Technicians:
1. Identify the major differences in treatment recommendations for dyslipidemia between the 2013 ACC/AHA Guidelines
and the new 2014 NLA Recommendations for Dyslipidemia.
2. List the classifications of lipoprotein lipid levels in adults.
3. Learn how the pharmacist can use NCA guidelines and the
ASCVD risk to assess and evaluate patients.

Introduction
Dyslipidemia, or high cholesterol, is a major risk
factor for the development of heart disease, the leading
cause of death in the United States (US).1 The Centers for
Disease Control and Prevention estimates that 71 million
Americans, roughly one-third of the entire population,
have high low-density lipoprotein (LDL) cholesterol.2 This
staggering number emphasizes the need for proper management of high cholesterol in the US and around the
world. Sadly, it’s estimated that only one-third of the 71
million Americans with high LDL are well-controlled.

This presents a significant public health challenge
for the medical community. Over the past decade
and a half, dyslipidemia management has been
the focus of numerous organizations, all aiming to
decrease the morbidity and mortality associated
with poor lipid control. And progress has been
made: the relative rate of death related to heart
disease has decreased by approximately 31%
from 2000-2010.3 However, there is much more
that still needs to be accomplished in the fight
against dyslipidemia.
Many organizations and agencies have compiled recommendations for the management of
dyslipidemia. Though commonalities exist, there
are stark differences between these varied guidelines. This continuing education article strives to
compare and contrast previous recommendations
with the recent National Lipid Association (NLA)
recommendations, as to provide a clear and comprehensive understanding of the varied approach
to management of dyslipidemia.
Background
Cholesterol, triglycerides and lipoproteins
comprise the major lipids in the human body and
when transported in the blood stream, are known
as lipoproteins. There are three major serum
lipoproteins: LDL, high-density lipoprotein (HDL)
and very low-density lipoprotein (VLDL) which are
carried in the blood as triglycerides (TG). Dyslipidemia is defined as a disorder of these key lipoproteins. This disease state may commonly be characterized by an elevation in total cholesterol, an
elevation in LDL, an elevation in TG, or a decrease
in HDL concentrations in the blood. Progression
of dyslipidemia is facilitated through a number of
mechanisms. As LDL levels increase in the blood,
the particles become lodged in the artery wall,
causing atherosclerotic lesions. Once in the artery
wall, LDL becomes oxidized, triggering an immune
response via macrophages. Macrophages, in an
attempt to engulf and clear the LDL particles,
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unintentionally cause an acceleration of LDL oxidation. Further involvement of the immune system
leads to an inflammatory response and formation
of atherosclerotic plaques. Eventually, after years of
repetitive vessel damage, formed plaques and cholesterol deposits begin to occlude blood vessels leading
to atherosclerotic cardiovascular disease (ASCVD).
ASCVD encompasses all cardiovascular disease that
is attributable to atherosclerotic plaque formation
including, but not limited to, myocardial infarction,
angina, and peripheral artery disease. It is this ASCVD
that is of most concern when discussing management
of dyslipidemia and prevention of cardiovascular
events.4
Timeline of Dyslipidemia Management
The past decade and a half has seen the update
and release of three distinct dyslipidemia guidelines. The first, produced by the National Cholesterol
Education Program (NCEP), were known as the Adult
Treatment Panel (ATP) guidelines. ATP I was released
in 1988 followed by ATP II in 1993. The most recent
and applicable update to these recommendations
was released in 2002 and was known as ATP III. The
ATP III recommendations focused on intensive LDL
lowering strategies mediated by goal-directed therapy as well as primary prevention in patients with
multiple risk factors.4 For many years, the ATP III
guidelines were the standard of care in clinical practice until the 2013 release of the American College of
Cardiology/American Heart Association (ACC/AHA)
dyslipidemia recommendations. The ACC/AHA 2013
guidelines demonstrated a shift in approach to lipid
management. While primary prevention remained a
focus, goal-directed therapy did not. Instead, intensive statin therapy became the center of the ACC/
AHA recommendations, with little regard to other
aspects of clinical management. Because the ACC/
AHA guidelines are still relatively new, their implementation and understanding in clinical practice is
still developing.
2013 ACC/AHA Guidelines Overview
The ACC/AHA expert panel took a different approach in regards to lipid management when compared to the ATP III guidelines. They determined that,
based on available evidence, there was no significant
morbidity or mortality benefit of titrating pharmacotherapy to target a specific LDL goal.5 In addition,
CONTINUING EDUCATION

the percentage of ASCVD risk reduction that one goal
level offered in comparison to another, for example lowering LDL-C to optimal (<100 mg/dL) versus
lowering it to near optimal (100-129 mg/dL), was
Table 1 - Statin Benefit Groups*

Individuals with clinical ASCVD
Individuals with primary elevation of LDL-C ≥190 mg/dL
Individuals age 40-75 with Diabetes Mellitus with LDL-C 70-189 mg/dL
Individuals without diabetes or clinical ASCVD who are 40-75 years of age with LDL-c 70-189 mg/dL and who
have an estimated 10-year ASCVD risk 7.5% or higher
*Adapted from reference 7

Table 2 - High- Moderate- and Low- Intensity Statin Therapy&*

High-Intensity Statin Therapy

Moderate-Intensity Statin Therapy

Daily dose lowers LDL-C on
average, by ≥ 50%
Atorvastatin 40-80 mg
Rosuvastatin 20-40 mg

Daily dose lowers LDL-C on
average, by 30-50%
Atorvastatin 10-20 mg
Rosuvastatin 5-10 mg
Simvastatin 20-40 mg
Pravastatin 40-80 mg
Lovastatin 40 mg
Fluvastatin 40 mg bid
Fluvastatin XL 80 mg^
Pitavastatin 2-4 mg^
*Individual response may vary between each patient in clinical
practice
^FDA approved but have not been evaluated by RCT’s
&
Adapted from reference 7

Low-Intensity Statin Therapy
Daily dose lowers LDL-C on
average, by ≤ 30%
Simvastatin 10 mg^
Pravastatin 10–20 mg
Lovastatin 20 mg
Fluvastatin 20–40 mg^
Pitavastatin 1 mg^

1

Figure 1 – Adapated from reference 7

never quantified in studies. Therefore, the idea that
the lowest level is best was not supported in the ACC/
AHA guidelines. They did, however, conclude that
evidence did support a significant morbidity and mortality benefit with moderate to high intensity statin
use. Based on this data, the panel concluded that the
sole focus of treatment should be on intensive statin therapy. Upon review of current clinical trial and
epidemiologic data, the ACC/AHA expert panel stated
that there were four specific “statin benefit” groups
(Table 1). Additionally, the panel advocated the use of
the Pooled-Cohort ASCVD Risk Calculator to further
identify high risk patients.6 There are a number of
online versions of this Pooled-Cohort calculator available to aid pharmacists in risk stratifying patients.
The ACC/AHA then classified the intensity of certain
statins for use in the previously discussed statin benefit groups (Table 2). The intensity of a statin was defined
by the percent reduction in LDL-C, as deduced from
systematic reviews of RCT’s. Finally, based upon an
individual’s ASCVD risk and statin benefit group, their
Summer 2015 • Arizona Journal of Pharmacy • 25
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need for a moderate or high intensity statin could be
determined. The ACC/AHA created a final algorithm to
guide statin therapy (Figure 1).
2014 NLA Recommendations Overview
The National Lipid Association (NLA) is an accredited, multidisciplinary organization consisting of
physicians, pharmacists, and other healthcare professionals and researchers whose focus is on enhancing
lipid management in clinical practice. The NLA Expert
Panel’s Recommendations for Patient-Centered Management of Dyslipidemia utilized current randomized
controlled data along with epidemiological and genetic
studies to determine beneficial interventions on clinical
ASCVD events.7 The panel focused on a patient-centered approach to lipid management and emphasized
the importance of clinical judgment based on individual factors. The NLA made six major evidence-based
conclusions which guided the formation of the recommendations:
1. An elevated level of cholesterol carried by circulating
apolipoprotein (apo) B-containing lipoproteins (nonHDL-C and LDL-C, termed atherogenic cholesterol) is a
root cause of atherosclerosis, the key underlying process contributing to most clinical ASCVD events.
In light of the recent compelling evidence found in
randomized-controlled trials (RCTs), epidemiological
and genetic studies, the NLA recommendations shift
away from the previous focus on LDL cholesterol as the
sole contributor to ASCVD risk. The expert panel concluded that non-HDL-C, in conjunction with LDL-C, are
the primary targets of therapy, with non-HDL-C being
a preferred primary target over LDL-C. This is because
non-HDL-C is thought to be a better predictor of ASCVD
morbidity and mortality as it includes the cholesterol
carried by all lipid particles that are potentially atherogenic. Therefore, non-HDL presumably provides a more
accurate picture of an individual patient’s risk. The
NLA suggests that a reduction in levels of atherogenic
cholesterol will proportionally reduce the risk of ASCVD
events in patients with dyslipidemia.
The NLA provides an optional secondary target for
treatment in certain patients. ApoB is a lipoprotein that
is found on the surface of LDL-C particles. Each LDL-C
particle contains one molecule of apoB; therefore, the
concentration of apoB in the bloodstream is directly
proportional to the number of circulating atherogenic
CONTINUING EDUCATION

particles. Unfortunately, apoB has not been consistently shown to be a superior measurement in
comparison to non-HDL-C and levels of apoB can be
altered by current statin use. These limiting factors
relegate the use of apoB to an optional target for
treatment. It is important to note that the pharmacological effect that statins have on cholesterol
levels is that it most often lowers cholesterol concentrations to a greater extent than it does apoB
levels. The apoB remaining after treatment goals
for non-HDL-C and LDL-C (see Table 3) are reached
is recognized as a contributor to any remaining ASCVD risk. Therefore, apoB levels may then be targeted to further reduce this risk after individuals reach
their goal levels for non-HDL-C and LDL-C.
2. Reducing elevated levels of atherogenic cholesterol will lower ASCVD risk in proportion to the
extent that atherogenic cholesterol is reduced. This
benefit is presumed to result from atherogenic
cholesterol lowering through multiple modalities,
including lifestyle and drug therapies.
The second major conclusion from the NLA
asserts that the amount that cholesterol is reduced
in the blood proportionally reduces ASCVD risk. A
meta-analysis evaluating the relationship between
non-HDL-C lowering and coronary heart disease risk
reduction compiled data from 14moderate to high
intensity statin dose placebo and active control trials. Researchers found that a 1% reduction in nonHDL-C resulted in a 4.5-year coronary heart disease
(CHD) relative risk reduction of 1%.8 It would stand
to reason that a greater reduction in atherogenic
cholesterol would result in an overall decreased risk
of cardiovascular events. This reduction is mediated by cholesterol-targeting medications, namely
statins, diet and exercise.
3. The intensity of risk-reduction therapy should
generally be adjusted to the patient’s absolute risk
for an ASCVD event.
The NLA based the recommendation for increased intensity of statin therapy in proportion to
an individual’s risk on current evidence and clinical
consensus. The conclusion is thus: as an individual’s
ASCVD risk increases, the need for greater reduction in atherogenic cholesterol is also required to
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prevent a cardiovascular event. This intensive decrease is mediated by the use of appropriate statin
therapy (Table 2). It stands to reason that if a greater
reduction of cholesterol is necessary, then a higher
intensity statin should be more efficacious than a
lower intensity statin. The Cholesterol Treatment Trialists’ Collaboration undertook meta-analyses of individual trial data examining the efficacy and safety of
lower versus higher intensity statin doses. Researchers found that higher intensity regimens resulted in
significantly fewer major vascular events [15% RR
(95% CI 11—18); p<0.0001], revascularization [19%
RR (95% CI 15—24); p<0.0001] and ischemic stroke
[16% RR (95% CI 5—26); p=0.005].9 Therefore, the
NLA’s third major conclusion is supported.
4. Atherosclerosis is a process that often begins early
in life and progresses for decades before resulting
in a clinical ASCVD event. Therefore, both intermediate-term and long-term/lifetime risk should be
considered when assessing the potential benefits and
hazards of risk-reduction therapies.
The basis of this major conclusion was founded
on the fact that there can be significant differences
between a patient’s short-term risk and their lifetime
risk. The NLA recommends avoiding a “one-size-fitsall” approach and instead advocates for a comprehensive work-up of each patient and an individual
treatment plan tailored to their specific short-term
and lifetime ASCVD risk.
5. For patients in whom lipid-lowering drug therapy
is indicated, statin treatment is the primary modality
for reducing ASCVD risk.
Statin therapy has proven to be the golden standard in dyslipidemia management. This stems from
the fact that statins provide the greatest percentage
LDL-C lowering and therefore, the greatest reduction
in cardiovascular risk. High intensity statins lower
LDL-C by an average of 50% from baseline whereas
moderate intensity statins provide a 30-50% reduction in LDL-C (Table 2). Alternative lipid-lowering therapies do not provide as substantial a mortality benefit
as statins and therefore are reserved as last-line
therapy if a patient is unable or unwilling to continue
statin therapy.
CONTINUING EDUCATION

6. Non-lipid ASCVD risk factors should also be managed appropriately, particularly high blood pressure,
cigarette smoking and diabetes mellitus.
ASCVD is multifactorial and involves more than
dyslipidemia management. Comorbid disease states
can further contribute to ASCVD risk, such as diabetes, hypertension and coronary artery disease. Additionally, poor diet and cigarette smoking compound
CHD risk. Smoking alone is attributed to 30% of all
CHD deaths in the United States, though this number
is likely higher.10 Addressing these additional risk factors in conjunction with proper dyslipidemia management can further decrease an individual’s ASCVD risk.
How the Guidelines Differ – Risk Assessment
When comparing the ACC/AHA guidelines with
the NLA recommendations, there are significant
differences that arise when assessing an individual’s
cardiovascular risk. While both guidelines similarly
define clinical evidence of ASCVD, the approach to
further risk stratification differs. The ACC/AHA utilizes
the Pooled-Cohort calculator to determine an individual’s 10-year risk of developing ASCVD. The combination of clinical ASCVD, age, and the 10-year risk score
all contribute to the ultimate decision of whether a
patient receives a moderate or high intensity statin.
The NLA on the other hand, only recommends using the Pooled-Cohort calculator as a supplement
when determining an individual’s treatment strategy.
Where the ACC/AHA only recommends the use of
their own calculator for further risk assessment, the
NLA gives the option of either the ATP III Framingham
risk calculator, the Framingham long-term (30-year),
or the ACC/AHA Pooled Cohort Equations calculator. The NLA acknowledges that scoring calculators
provide only an estimate of risk for these patients,
and should be used as a means of more accurately
reclassifying moderate risk individuals as high risk for
optimal treatment outcomes.7 The NLA recommends
consideration of other factors that may influence
risk categorization to the high risk category for more
appropriate treatment goals. The presence of metabolic syndrome and other clinical risk indicators that
warrant the use of the Pooled-Cohort calculator are
outlined in Table 8. The ACC/AHA on the other hand
incorporates the risk calculator into assessing risk for
determining appropriate statin intensity for two of
the four statin benefit groups: patients with diabeSummer 2015 • Arizona Journal of Pharmacy • 27
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tes type 1 or 2 age 40-75 years, and patients without
diabetes age 40 to 75 years with a 10-year assessment
score of ≥ 7.5%.7
For patients that fall under the high or very-high
risk categories, the NLA states that quantitative risk
scoring is not necessary when certain disease states
are also present. These conditions include diabetes
mellitus type 1 or 2, chronic kidney disease stage 3B
or greater, LDL-C ≥190mg/dL (severe hypercholesterolemia) and the presence of ASCVD. The NLA argues that
quantitative risk scoring in these patients often results
in underestimation of the patients true risk for an ASCVD event, and should therefore be avoided to allow for
a more accurate determination of patient treatment
options.7 Individuals in the moderate risk category with
two major risk factors for ASCVD (Table 5) are often risk
assessed for purpose of evaluating pharmacotherapy
when these uncertainties still exist despite their risk
category. The greatest benefit of quantitative risk scoring in moderate risk patients is in determining if justification exists for initiating pharmacotherapy when it
may have otherwise been held. So in general, the NLA
give clinicians the option of performing quantitative
risk scoring for patients without high risk conditions
who nonetheless may be at an increased risk of an
ASCVD event, or for those who have higher risk factors
warranting further consideration. As emphasized previously, this approach differs from the ACC/AHA Guidelines that utilize quantitative risk scoring as an essential
part of the ASCVD classification system.
How the Guidelines Differ – Treatment Goals
While the ACC/AHA guidelines make no direct assessment to which lipid measurement correlates greatest with ASCVD risk, the NLA expert panel recognizes
non-HDL as a superior treatment target compared to
the traditionally measured LDL-C. The expert panel discusses that non-HDL accounts for more types of cholesterol that contribute to ASCVD, and that non-HDL-C
better predicts morbidity and mortality over LDL-C.7,11
Target treatment goal recommendations may be the
most significant difference between the ACC/AHA
guidelines and the NLA recommendations. The ACC/
AHA guidelines decision to not target treatment goals
was based upon their review of 23 RCTs for primary
and secondary prevention (6 for primary and 19 for
secondary with 2 studies encompassing both populations-ASPEN and AURORA) and was two of their
three critical questions that they addressed while
CONTINUING EDUCATION

formulating their guidelines. The authors did not
find enough data in these studies to support the
use of specific treatment goals.7 On the contrary,
even though the NLA expert panel recognizes in
their review of available RCTs that treating patients to specific atherogenic cholesterol goals
have not been tested as primary efficacy, they view
treatment goals as a necessary measure in the
management of dyslipidemia. The NLA states that
implementing treatment goals enhances patient-clinician communication and assures that appropriate
risk reduction is occurring. The specific goals for
each risk group in the NLA guidelines are outlined
in Table 9.Finally, when comparing the ACC/AHA
and NLA treatment goals, it is important to analyze
follow-up recommendations. The ACC/AHA suggest an initial baseline fasting lipid panel at time of
pharmacotherapy initiation and follow up at 4 to 12
weeks to access for adherence to pharmacotherapy and lifestyle modifications. Once a patient has
been stabilized on pharmacotherapy, the ACC/AHA
suggests follow-up every 3-12 months thereafter.5
The NLA guidelines recommend similar time frames
for follow up with multiple visits over 6 months in
which target goal levels should be obtained, and
once goal has been reached follow up should occur
every 4 to 12 months.7
Pharmacotherapy Management
The pharmacist’s role in dyslipidemia management is applicable across multiple patient care
settings. Whether in an inpatient or outpatient
setting, a pharmacist’s understanding of basic
monitoring, adverse events, and laboratory values
are crucial in providing the best care to individual
patients. In addition to a fasting lipid panel periodically as recommended above, liver function tests
(LFTs) should be evaluated at baseline, and creatine
kinase (CK) should be evaluated in select patients.
However, routine monitoring of these lab values is
not currently recommended and should only be repeated upon a patient’s symptomatic presentation
or based upon clinical judgment.12
Pharmacists should monitor for side effects of
statin therapy, the most common of which are muscle pain and weakness, and gastrointestinal upset
and headache. More severe adverse effects include
myopathies and rhabdomyolsis, though the incidence is rare. Pharmacists should evaluate patients
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muscle pain and recommend laboratory testing of LFTs
or CK if indicated. In those patients who present with
muscle pain, symptoms may improve upon switching
to a different statin. Other strategies suggested by the
NLA include a modified dosing regimen, such as every
other day, or lowering the total daily dose. For those
patients who absolutely cannot tolerate a statin, other
classes of medications may be considered, either alone
or in addition to the statin (Table 6). Of note, the NLA
does not support the use of combination drug therapy
prior to reaching the maximum tolerated statin dose,
as evidence justifying this is lacking.
Additionally, pharmacists should evaluate the potential for drug-drug interactions. Simvastatin, atorvastatin and lovastatin are substrates for CYP3A4 and
are therefore, the three statins most likely to interact
with other medications. CYP3A4 inhibitors are of most
concern, as they can increase serum concentrations
of these statins and put patients at an increased risk
of toxicity. However, atorvastatin is less reliant on
3A4 for metabolism and is involved in fewer clinically
significant interactions when compared to simvastatin
and lovastatin. Gemfibrozil inhibits glucuronidation,
an important elimination pathway for all statins and
should therefore be avoided with all statin therapy.
Fenofibrate is an appropriate alternative to gemfibrozil and appears to be safe and effective when used
with statins.13 Finally, patients should be counseled on
avoidance of grapefruit juice while taking simvastatin
and lovastatin due to inhibition of 3A4. Consumption
is not contraindicated in atorvastatin use but intake
should be limited to less than 1 liter per day. Table 7
lists other potential drug-drug interactions with select
statin therapies.
Finally, patients with severe hypercholesterolemia
(LDL-C ≥190 mg/dL) can present significant treatment
challenges. Even with combination therapy, goal levels
of atherogenic cholesterol may not be achievable in
this despite utilizing the most aggressive treatment
options tolerable. In an effort to reduce morbidity and
mortality in patients with severe hypercholesterolemia,
the NLA recommends a reduction in atherogenic cholesterol by at least 50% instead of the standard goals
outlined in Table 3. Although new medication classes
are being studied that may eventually make the standard goals in this year’s recommendations achievable
in patients with excessively elevated cholesterol levels,
this alternative treatment approach remains the most
practical option until new agents are proven safe and
CONTINUING EDUCATION

efficacious.
Therapeutic Lifestyle Changes
The ACC/AHA and the NLA recognize the importance of lifestyle modifications as a key component
of dyslipidemia management. The expert panel
recommends a 3-month trial of lifestyle therapy
for patients who fall into the low to moderate risk
categories prior to drug therapy. For high and very
high risk patients, however, drug therapy may be
initiated at the same time as lifestyle therapy.
Lifestyle changes should be a focus at every
visit, with an emphasis on diet, exercise and smoking cessation. Patients with dyslipidemia should
be educated on how to maintain a balanced diet,
low in saturated fats and sodium and high in fiber.
The DASH diet and the AHA’s dietary recommendations are all highly recommended diet plans and
can aid in both cholesterol and blood pressure
reduction.14,15 While pharmacists can provide basic
nutritional education and support, referral to a
registered dietician is recommended. Additionally,
moderate to high intensity exercise ideally targeting
150 minutes per week (30 minutes per day for 5
days) is highly encouraged. For those patients who
are overweight or obese, a weight loss of 5% to
10% of body weight over 6 months is recommended. Smoking cessation should be encouraged at
each follow-up and referral to patient resources,
should be provided as needed.
Conclusion
Clinical practices in the medical community are
constantly adapting as new data becomes available. This is illustrated by the rapidly changing lipid
recommendations over the past decade and a half.
A thorough review of the 2013 ACC/AHA guidelines in comparison to the newly released 2014
NLA recommendations reveals both commonalities as well as differences. The release of the NLA
recommendations saw the resurrection of lipid
goals while retaining the focus on intensive statin
therapy. As a pharmacist, it is fundamental to have
an understanding these current practice guidelines
and familiarize oneself with the preceding relevant
recommendations.
Pharmacists play a significant role in the management of patients with dyslipidemia. They are
some of the most accessible members of the health
Summer 2015 • Arizona Journal of Pharmacy • 29
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care team and are convenient resources for patients. They have
the potential to make substantial interventions in patient care,
involving encouragement of therapeutic lifestyle changes, adverse drug event monitoring, and medication adherence. Given
that pharmacists work closely alongside medical practitioners, it
is essential to remain up to date on the current evidence based
guidelines, as to provide accurate and timely pharmacotherapy
recommendations.

Table 3 – NLA Classifications of Cholesterol and
Triglyceride levels in mg/dL
Non-HDL-C
<130
130-159
160-189
190-219
≥220

Desirable
Above desirable
Borderline high
High
Very high

LDL-C
<100
100-129
130-159
160-189
≥190

Desirable
Above desirable
Borderline high
High
Very high

HDL-C
<40 (men)
<50 (women)

Low
Low

Triglycerides
<150
150-199
200-499
≥500

Table 4 – NLA Risk Assessment
Major Risk Factors for
ASCVD

Evidence of Clinical ASCVD
Criteria

High or Very High Risk Patient
Groups

 Age
- Male ≥45 years
- Female ≥55 years
 Family history of early CHD
- Male <55 years of age first
degree relative
- Female <65 years of age
first-degree relative
 Current cigarette use
 High blood pressure
(≥140/≥90 mmHg) or on
blood pressure medication
 Low HDL-C
- Male <40 mg/dL
- Female <50 mg/dL

 MI or ACS
 Coronary or other
revascularization procedure
 Ischemic stroke or TIA
 Atherosclerotic peripheral arterial
disease
- Includes ankle/brachial index
<0.90
 Other documented atherosclerotic
diseases such as:
- Coronary atherosclerosis
- Renal atherosclerosis
- Aortic aneurysm secondary to
atherosclerosis

Quantitative risk scoring is not
necessary for initial risk assessment
in patients with the following
conditions:
 Diabetes mellitus, Type 1 or 2
 Chronic kidney disease, stage ≥3B
 LDL-C ≥190 mg/dL or severe
hypercholesterolemia phenotype
 ASCVD

Adapted from reference 8

Table 6 - Lipoprotein Metabolism of Other Agents

Adapted from reference 8

Table 5 - Comparison of ACC/AHA and NLA Treatment Goals
2013 ACC/AHA Guidelines
No recommendation for non-HDL-C vs. LDL-C

Recommends monitoring of non-HDL-C over LDL-C

2

 Excludes target lipid goals
 4 statin benefit groups
1. Clinical ASCVD
2. LDL-C ≥190 mg/dL
3. 40-75 years old with DM (I or II)
4. Absence of ASCVD or DM, 40-75 years
old with LDL-C 70-189mg/dL and an
estimated 10-year ASCVD risk ≥ 7.5%

 Utilizes treatment lipid goals and pharmacotherapy
therapy intervention levels
 Risk Category Target Goal (Non-HDL-C, LDL-C)
1. Low
(<130, <100)
2. Moderate (<130, <100)
3. High
(<130, <100)
4. Very High (<100, <70)

Follow up visit in 4 to 12 weeks to assess
adherence, then every 3 to 12 months

Goal levels should be reached by approximately 6
months, then follow-up every 3-12 months

Effects

LDL-C
Non-HDL-C
HDL-C
TG

↓15-30%
↓4-16%
↑3-5%
↓0-10%

Nicotinic Acids

LDL-C
Non-HDL-C
HDL-C
TG

↓5-25%
↓8-23%
↑15-35%
↓20-50%

Fibric Acids

LDL-C
Non-HDL-C
HDL-C
TG

↓5-20%
↓5-19%
↑10-20%
↓20-50%

Cholesterol
Absorption Inhibitor

LDL-C
Non-HDL-C
HDL-C
TG

↓13-20%
↓14-19%
↑3-5%
↓5-11%

Long-Chain Omega-3
Fatty Acids

LDL-C
Non-HDL-C
HDL-C
TG

↓6%-↑25%
↓5-14%
↑5%-↓7%
↓19-44%

Table 7 - Statin Metabolism

Table 9 - NLA Criteria for ASCVD Risk Assessment, Treatment Goals for Atherogenic Cholesterol, and
Levels at Which to Consider Drug Therapy
Risk category

Criteria

Treatment goal
Non-HDL-C mg/dL
LDL-C mg/dL
Apo B mg/dL*

Consider drug therapy
Non-HDL-C mg/dL
LDL-C mg/dL
Apo B mg/dL*

Low

 Major ASCVD risk factors
 Consider other risk factors, if known

<130
<100
<90*

≥190
≥160

Moderate

 2 major ASCVD risk factors
 Consider quantitative risk scoring
 Consider other risk indicators

<130
<100
<90*

≥160
≥130

High

 ≥3 major ASCVD risk factors
 Diabetes mellitus (type 1 or 2)
- 0-1 other major ASCVD risk factors and
- No evidence of end organ damage
 Chronic kidney disease stage 3B or 4
 LDL-C ≥190 mg/dL (severe
hypercholesterolemia)
 Quantitative risk score reaching the highrisk threshold

<130
<100
<90*

≥130
≥100

 ASCVD
 Diabetes mellitus (type 1 or 2)
- ≥2 other major ASCVD risk factors or
- Evidence of end organ damage

<100
<70
<80*

≥100
≥70

For patients with ASCVD or diabetes mellitus, consideration should be given to use of moderate or high-intensity
statin therapy, irrespective of baseline atherogenic cholesterol levels.
*Apo B is a secondary, optional target of treatment
Adapted from reference 8
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Lipoproteins

Bile Acid
Sequestrants

Adapted from reference 8

Adapted from reference 8

Very High

Drug class

2014 NLA Recommendations

1

3

Normal
Borderline high
High
Very high

Statin

Metabolic
Pathway

Potential Interactions

Lovastatin
Simvastatin
Atorvastatin

3A4

Ketoconazole, itraconazole,
cyclosporine, erythromycin,
clarithromycin, ritonavir
Gemfibrozil

Rosuvastatin

Minimal 2C9

Cyclosporine, gemfibrozil

Fluvastatin

2C9, 3A4, 2D6

Warfarin, gemfibrozil

Pitavastatin

Minimal 2C9

Gemfibrozil

Pravastatin

None
significant

Gemfibrozil

Adapted from reference 17

Table 8 - Criteria for Clinical Identification of Metabolic Syndrome
Measure

Criteria

1.

Elevated waist circumference

≥40 inches in men
≥35 inches in women

2.

Elevated triglycerides*

≥150 mg/dL

3.

Reduced HDL-C

<40 mg/dL in men
<50 mg/dL in women

4.

Elevated blood pressure*

Systolic ≥130 and/or diastolic ≥85 mm Hg

5.

Elevated fasting glucose*

≥40 inches in men
≥35 inches in women

*Drug treatment with a triglyceride-lowering agent, drug treatment of elevated blood
pressure, and drug treatment of elevated blood glucose are alternative indicators for
metabolic syndrome
Adapted from reference 8

Dyslipidemia
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